Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApollomicsAPLM +1.57%29 Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 29/100. The stock has 5 warning signs investors should review. Among 840 Biotechnology companies, Apollomics ranks worse than 87.14% on this metric.
Apollomics (NAS:APLM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Apollomics Days Sales Outstanding Related Terms
Apollomics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Apollomics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLM vs RNXT, ELOX, HYPD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Apollomics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Apollomics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apollomics (APLM) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Apollomics and its competitors. Over the past decade, Apollomics' Days Sales Outstanding has ranged from 98.98 to 204.08. According to the industry distribution chart, Apollomics ranks #732 out of 840 companies in the Biotechnology industry, placing it in the top 87.1%.
Is Apollomics' Days Sales Outstanding too high?
Apollomics' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 98.98 to a high of 204.08. Based on the distribution chart, Apollomics ranks #732 out of 840 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Days Sales Outstanding compare to RNXT and ELOX?
According to the Biotechnology industry distribution chart, Apollomics ranks #732 out of 840 companies for Days Sales Outstanding. This places Apollomics in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Historically, Apollomics' own Days Sales Outstanding has ranged from 98.98 to 204.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Apollomics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Apollomics' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Apollomics (APLM), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
29GF Score
Get the complete analysis for APLM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLM has been successfully added to your 
